Sign up
Pharma Capital
EPIC: ZYNE
Market: NASDAQ
52-week High/Low: $16.46 / $2.82
Sector: Pharma & Biotech
Market Cap: $308.96M
Website: zynerba.com

At Zynerba Pharmaceuticals, our team is dedicated to developing next-generation transdermally-delivered cannabinoid therapeutics for patients affected by rare and near-rare neuropsychiatric conditions. Often, these diseases have few, if any, treatment options and can leave patients and their families feeling helpless and alone. Zynerba is committed to developing breakthrough therapies to...

Zynerba Pharmaceuticals

zynerba.com

Interactive graph

col 3
col 4
col 5
col 6

Big picture - Why invest in Zynerba Pharmaceuticals

Zynerba Pharmaceuticals Snapshot

View full ZYNE profile View Profile
View All

Market Reports Including ZYNE

VIEW ALL

Executive video interviews

VIEW ALL VIDEOS

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.